Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control

Top Things to Know

The produce prescription program did not significantly improve glycemic control or other health metrics.

The COVID-19 pandemic posed significant challenges to program implementation and effectiveness, which highlights the limitation and challenges faced during disruptive periods.

Despite high voucher redemption rates, the study suggests a need for program modifications, such as increased voucher amounts or longer durations, to improve effectiveness.

Summary of Conclusion/Findings

The study evaluated the impact of a produce prescription program on glycemic control among patients with diabetes during the COVID-19 pandemic. Conducted with 252 participants receiving $60 monthly vouchers for six months, the study found no significant difference in HbA1c levels between the treatment and control groups. Secondary outcomes, including blood pressure and BMI, also showed no significant changes. The study highlights the challenges of implementing such programs during disruptive periods like the pandemic.